Endpoints News did an exclusive interview with bit.bio's CEO after the cell therapy pipeline announcement with an initial focus on the liver.
17.11.2023
bit.bio named as one of the WIRED Trailblazers in Cambridge
WIRED have named 16 Trailblazer companies in Cambridge that are pushing boundaries and scaling up - including bit.bio.
Five things you need to succeed as a leader - Authority Magazine Q&A
Authority Magazine interviewed bit.bio's SVP of tech ops and manufacturing Kathryn Golden to discover her path to leadership and w...
Navigating the future of cell therapies with exec Kathryn Corzo
Our President and COO Kathryn Corzo talks with editor Brian Buntz from Drug Discovery & Development.
.png)
The UK has the chance to lead the way in synbio. We must grasp it.
An article on synbio in the Summer 2023 issue of Science in Parliament magazine. Authored by our founder and CEO Mark Kotter.
Synthetic biology: impacting drug discovery
Our CEO Mark Kotter talks to Drug Discovery World about different approaches to synthetic biology and its applications in drug dis...
.png)
proto.life feature on industrial manufacture of human cells
This in depth feature covers bit.bio's breakthrough reprogramming approach and ability to manufacture human cells at industrial sc...
The power of automation featured in Scientist Live
Kathryn Golden, SVP Technical Operations & Cell Manufacturing, discusses how our opti-ox technology lends itself to scale through ...
iNews feature on consistency data presented at ISSCR by bit.bio
The piece covers bit.bio's breakthrough in industrialising the consistent manufacture of human cells and how this will transform h...